Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer. Their product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness.